MedTrace Logo

Does Personality Predict Patient Adherence, Health Behaviors, and Weight Loss Outcomes During the Latino Crossover Semaglutide Study (LCSS)? (Story-LCSS Project)

NCT05622045 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2025-08-07

No results posted yet for this study

Summary

The goal of this observational study is to learn about the personality attributes and values of people living with obesity that are part of the Latino community, and how these personality attributes and values can help to predict success during a weight loss program.

The main questions it aims to answer are:

* What are the personality attributes and values of people living with obesity that sign up to the LCSS-Latino Crossover Semaglutide Study trial?
* Can behavioral artificial intelligence (a computer formula) predict which patients will complete the LCSS-Latino Crossover Semaglutide Study trial?
* How do behavioral artificial Intelligence predictions (a computer formula) compare to clinician predictions of patient success?
* Can behavioral artificial intelligence (a computer formula) predict patient weight loss, calorie consumption and physical activity levels during the LCSS-Latino Crossover Semaglutide Study trial? Participants will be recorded in English and Spanish while responding to a question regarding participation in a weight loss study.

Conditions

Interventions

BEHAVIORAL

Voice data

Recorded response to a question about their participation in a weight loss study.

Sponsors & Collaborators

  • Scaled Insights

    collaborator INDUSTRY

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Celine Heskey, DrPH · Loma Linda University

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2024-05-29
Completion
2026-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05622045 on ClinicalTrials.gov